Flag­ship's merged biotech Reper­toire nets ex-Pfiz­er CSO An­tho­ny Coyle as R&D chief

Flag­ship is build­ing a big-name C-suite at its new, $220 mil­lion merged biotech.

Reper­toire Im­mune Med­i­cines, which al­ready boasts for­mer Biover­a­tiv chief John Cox as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER